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Particulate air pollution remains a threat to
public health despite the decline in the
ambient concentration in the past decades.
It has been estimated by the World Health
Organization that particulate matter (PM)
exposure accounts for 800,000 deaths per
year worldwide (Brook et al. 2004). The
increased mortality has been attributed to res-
piratory and more recently to cardiovascular
compromise (Borja-Aburto et al. 1998; Brook
et al. 2004; Dockery 2001). Short-term expo-
sure to polluted air for as little as 2 hr
increases the risk of myocardial infarction in
people at risk of developing cardiovascular
disease (Peters et al. 2001). 
Various mechanisms have been proposed
to explain the cardiovascular health effects of
PM. These hypotheses include pulmonary
and systemic oxidative stress and inflamma-
tion (Gurgueira et al. 2002), direct vasocon-
striction (Huang et al. 2002; Li et al. 2005a),
enhanced coagulation pathways (Nemmar
et al. 2002b), and altered cardiac autonomic
function (Gold et al. 2000). The ultrafine
fraction of ambient pollutant particles [diam-
eter < 100 nm, ultrafine particles (UFPs)]
may represent a particular concern because
these small particles can remain airborne for
an extended period of time. Although they
represent only a relatively small fraction of
the total mass (Peters et al. 1997), UFPs are a
substantial component of PM in the number
of particles. Once inhaled, UFPs can be
deposited in greater numbers in deeper lung
zones than larger particles (Nemmar et al.
2002b) and have a greater potential to perme-
ate the alveolar capillary barrier to be in con-
tact with vascular endothelial cells. 
To better understand how UFPs may
affect vascular endothelial cells, we profiled
gene expression in human pulmonary arterial
endothelial cells (HPAEC) exposed to UFPs
in Chapel Hill, North Carolina. We hypothe-
size that UFPs would induce transcriptional
activation of genes related to the coagulation
and inflammatory response which are signs
of endothelial cell dysfunction. Cultured
HPAEC were treated with Chapel Hill UFPs
(100 µg/mL) or control for 4 hr. RNA from
these samples was hybridized to Affymetrix
HG U133 Plus 2.0 chips and analyzed for dif-
ferentially expressed genes. We found that tis-
sue factor (F3, Unigene accession no. 62192;
http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=unigene), coagulation factor II recep-
tor-like 2 (F2RL2; Unigene accession no.
42502), interleukin 6 (IL-6, Unigene accession
no. 512234) and interleukin 8 (IL-8; Unigene
accession no. 624) were up-regulated. We fur-
ther showed that the release of IL-6 and IL-8
induced by UFP was partially dependent on
the activation of the tissue factor pathway. 
Materials and Methods 
Reagents and chemicals. Molecular mass
standards, polyacrylamide, buffers, and protein
assay reagents were purchased from Bio-Rad
(Richmond, CA). The enhanced chemilumi-
nescent (ECL) blotting detection reagents were
purchased from Amersham Biosciences Corp.
(Piscataway, NJ). TaqMan Universal PCR
master mix and Taqman Gene Expression pre-
developed assays (reagents concentrated and
preoptimized mixes of primers and FAM-
labeled TaqMan probes) for tissue factor (F3),
coagulation factor II receptor-like 2 (F2RL2),
coagulation factor VIII associated (F8A1,
Unigene accession no. 533543; http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db=
unigene), and heme oxygenase 1 (HMOX1;
Unigene accession no. 517581) were obtained
from Applied Biosystems (Foster City, CA).
All other chemicals and reagents were from
Sigma-Aldrich Co. (St. Louis, MO) unless
stated otherwise. 
Collection and extraction of Chapel Hill
UFPs. UFPs were collected in July of 2002 in
Chapel Hill, North Carolina, outside the U.S.
Environmental Protection Agency Human
Studies Facility as described previously
(Becker et al. 2005). The elemental composi-
tion of the UFPs (nanograms per milligram)
was described previously with aluminum
(948), copper (150), iron (879), lead (181),
silicon (1098), and zinc (669) representing the
most abundant constituents (Becker et al.
2005). UFP were resuspended in sterile H2O
(5.0 mg/mL) and stored at –80°C. 
Preparation of the water-soluble and
-insoluble fractions of UFP. Water-suspended
UFPs were diluted to 25 and 100 µg/mL, cen-
trifuged for 30 min at 20,000 × g, and the
supernatants were collected as the water-soluble
fractions. Pellets from the centrifugation were
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BACKGROUND: Epidemiology studies have linked exposure to pollutant particles to increased
cardiovascular mortality and morbidity, but the mechanisms remain unknown. 
OBJECTIVES: We tested the hypothesis that the ultrafine fraction of ambient pollutant particles
would cause endothelial cell dysfunction. 
METHODS: We profiled gene expression of human pulmonary artery endothelial cells (HPAEC)
exposed to ultraﬁne particles (UFPs; 100 µg/mL) from Chapel Hill, North Carolina, or vehicle for
4 hr with Affymetrix HG U133 Plus 2.0 chips (n = 4 each). 
RESULTS: We found 320 up-regulated genes and 106 down-regulated genes (p < 0.01, 5% false dis-
covery rate). We noted up-regulation of genes related to coagulation [tissue factor (F3) and coagula-
tion factor II receptor-like 2 (F2RL2)] and differential regulation of genes related to F3 signaling
(FOS, JUN, and NFKBIA). Results of quantitative polymerase chain reaction show a signiﬁcant up-
regulation of F3 after 10 and 100 µg/mL UFP exposures. Additionally, the water-soluble fractions
of UFPs were sufﬁcient to induce the expression of F3, F2RL2, and heme oxygenase 1 (HMOX1).
Treatment of HPAEC with UFPs for 16 hr increased the release of interleukin (IL)-6 and IL-8.
Pretreatment of HPAEC with a blocking antibody against F3 attenuated IL-6 and IL-8 release by
30 and 70%, respectively. 
CONCLUSIONS: Using gene proﬁling, we discovered that UFPs may induce vascular endothelial cells
to express genes related to clotting. These results indicate that PM may cause adverse cardiovascular
health effects by activating coagulation-inﬂammation circuitry. 
KEY WORDS: coagulation cascade, human endothelial cells, microarray, particulate matter, tissue
factor. Environ Health Perspect 115:535–540 (2007). doi:10.1289/ehp.9556 available via
http://dx.doi.org/ [Online 8 January 2007]washed with deionized distilled water 3 times
and resuspended in the appropriate volume of
water. We designated this as the water-insoluble
fraction. Both fractions were stored at –80°C. 
Human pulmonary artery endothelial cells.
For microarrays, HPAEC (Cell Applications,
Inc., San Diego, CA) were cultured in endo-
thelial growth medium (EGM-2, Clonetics
Bio Whittaker Inc., Walkersville, MD), grown
to 80% confluency in 100-mm petri dishes,
and used during passages 3–5. UFPs were
diluted with EGM-2 before experiments. Cells
were treated with UFPs (100 µg/mL) or vehi-
cle control for 4 hr at 37°C. For all other
experiments, HPAEC were grown to 80%
conﬂuency in 6-well plates. 
Two different quantitative polymerase
chain reaction (Q-PCR) experiments were con-
ducted with UFPs and water-soluble and -insol-
uble fractions. HPAEC were treated for 4 hr (0,
1, 10, and 100 µg/mL UFP) for F3 Q-PCR
analysis or 2 and 24 hr (0, 25, and 100 µg/mL
water-soluble and -insoluble UFP fractions) for
all F3, F2RL2, F8A1, and HMOX1.
RNA isolation. RNA was extracted with
Trizol reagent (GIBCO BRL Life Technologies,
Gaithersburg, MD) and puriﬁed with Qiagen
RNeasy mini columns (Qiagen, Valencia,
CA) according to manufacturers’ protocols.
Total RNA was resuspended in RNase-free
water and assessed with the Agilent 2100
Bioanalyzer and RNA 6000 Nano assay
(Agilent Technologies, Palo Alto, CA). All
RNA samples had a 28S/18S ratio ≥ 1.8 and
were stored at –80°C before shipment on dry
ice to Expression Analysis Inc. (Durham, NC). 
Microarray target preparation and
hybridization. RNA target preparation and
hybridization to the Affymetrix HG U133
plus 2.0 GeneChip oligonucleotide microar-
ray (Affymetrix, Inc., Santa Clara, CA) was
performed by Expression Analysis, Inc. as
described previously (Li et al. 2005b).
Fluorescent images were detected in a
GeneChip Scanner 3000 and expression data
was extracted using the default settings in the
Microarray Suite 5.0 software (Affymetrix).
All GeneChips were scaled to a median inten-
sity setting of 500. For microarray purposes,
four biological replicates were collected each
for the treated and control samples. 
Q-PCR. Q-PCR was performed for
selected genes. cDNAs were synthesized from
0.4 µg of total RNA in 100 µL of buffer con-
taining 5 µM random hexaoligonucleotide
primers (Pharmacia, Piscataway, NJ), 10 U/µL
Moloney murine leukemia virus reverse tran-
scriptase (GIBCO BRL Life Technologies),
1 U/µL RNase inhibitor (RNasin, Promega,
Madison, WI), 0.5 mM dNTP (Pharmacia),
50 mM KCl, 3 mM MgCl2, and 10 mM
Tris–HCl (pH 9.3) for 1 hr at 39°C. Reverse
transcriptase was heat inactivated at 94°C for
4 min.
Q-PCR of specimen and standard cDNA
was completed using TaqMan predeveloped
assay reagents. Quantitative fluorogenic
ampliﬁcation of cDNA was performed using
the ABI Prism 7500 Sequence Detection
System, primers and probes of interest and
TaqMan Universal PCR Master Mix (Applied
Biosystems). The relative abundance of
mRNA levels was determined from standard
curves generated from a serially diluted stan-
dard pool of cDNA prepared from control
HPAEC cultures. The relative abundance of
glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, Unigene accession no. 544577;
http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=unigene) mRNA was used to normal-
ize levels of the mRNAs of interest. For
Q-PCR veriﬁcation experiments, RNA from
at least three additional experiments was col-
lected for each timepoint and concentration.
RNA samples for microarray and Q-PCR
were collected from different experiments and
do not represent the same sample. 
Experiments with anti-tissue factor anti-
body. HPAEC were pretreated with a mono-
clonal blocking antibody against human F3
(product number 4509; American Diagnostica,
Inc., Stamford, CT) (0, 50, and 100 ng/mL)
for 15 min with gentle rocking before
addition of UFPs (100 µg/mL) or control.
UFPs were sonicated for 10 min before addi-
tion to cultures. Cell cultures were then incu-
bated for 16 hr at 37°C. Supernatants were
removed, centrifuged for 10 min at 150 × g
at 4°C, and stored at –80°C. IL-6 and IL-8
protein levels in supernatant samples (R&D
Systems, Inc., Minneapolis, MN) were deter-
mined by immunoassay according to the
manufacturer’s recommendation. Three bio-
logical replicates were run in duplicate for
each dose and assay. 
Protein isolation and Western blot analy-
sis. After exposure, HPAEC cells were lysed
with 500 µL RIPA buffer (1% Nonidet P-40,
0.5% sodium deoxycholate, and 0.1% SDS
in phosphate buffered saline (PBS), pH 7.4)
containing 1 µL protease inhibitor cocktail
(Sigma-Aldrich Co.) per 100 µL RIPA
(radioimmunoprecipitation) buffer and
sheered with a 22-ga needle. Lysates were cen-
trifuged 10 min at 150 × g, 4°C, and stored at
–80°C. Protein concentration of cell lysates was
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Table 1. Cytokine–cytokine receptor interaction KEGG pathway (p = 0.001) identiﬁed with DAVID 2.1 from
the list of differentially expressed unique genes (p < 0.01) (FDR = 0.05). 
Accession no. Gene symbol Gene name Fold change
303649 MCP1 chemokine (C-C motif) ligand 2 2.6
624 IL8 interleukin 8 2.5
89690 CXCL3 chemokine (C-X-C motif) ligand 3 2.3
512234 IL6 interleukin 6 2.3
396530 HGF hepatocyte growth factor 2.2
590921 CXCL2 chemokine (C-X-C motif) ligand 2 2.0
204044 TNFRSF11A tumor necrosis factor receptor, superfamily member 11A  1.8
389874 TSLP thymic stromal lymphopoietin 1.6
557403 IL1R1 interleukin-1 receptor, type I 1.6
513457 IL4R interleukin 4 receptor  1.5
2250 LIF leukemia inhibitory factor 1.5
789 CXCL1 chemokine (C-X-C motif) ligand 1 1.4
28792 INHBA inhibin, beta a 1.4
479756 KDR kinase insert domain receptor  1.3
438918 ACVR1B activin A receptor, type IB 1.3
421986 CXCR4 chemokine (C-X-C motif) receptor 4 1.3
1048 KITLG kit ligand 1.3
1976 PDGFB platelet-derived growth factor beta polypeptide 0.8
256278 TNFRSF1B tumor necrosis factor receptor, superfamily member 1B 0.8
Gene annotations are from Unigene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene).
Table 2. Wnt signaling KEGG pathway (p = 0.02) identified with DAVID 2.1 from the list of differentially
expressed unique genes (p < 0.01) (FDR = 0.05). 
Accession no. Gene symbol Gene name Fold change
211869 DKK2 dickkopf homolog 2 1.9
592141 NFATC2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 1.8
599590 SOX17 SRY (sex determining region Y)-box 17 1.4
6347 LRP5 low density lipoprotein receptor-related protein 5 1.3
525704 JUN v-jun sarcoma virus 17 oncogene homolog 1.3
283565 FOSL1 fos-like antigen 1 1.2
351887 CAMK2B calcium/calmodulin-dependent protein kinase II beta 1.2
149413 PPP3CC protein phosphatase 3, catalytic subunit, gamma 1.2
isoforms (calcineurin A gamma)
94234 FZD1 frizzled homolog 1 0.8
591968 FZD4 frizzled homolog 4 0.8
524348 PRICKLE1 prickle-like 1 0.8
Gene annotations are from Unigene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene). measured with Bio-Rad protein assay reagents
according to manufacturer instructions. 
For Western blot analysis, cellular proteins
were loaded equally, separated by 10%
sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and transferred to a polyvinyli-
dene diﬂuoride membrane. The blot was then
blocked with 5% milk in PBS with 0.05%
Tween-20 for 1 hr at room temperature,
washed briefly, then probed with a mono-
clonal antibody against tissue factor (product
number 4509; American Diagnostica, Inc.)
overnight at 4°C followed by incubation with
a horseradish peroxidase–conjugated goat anti-
mouse antibody (Santa Cruz Biotechnology,
Santa Cruz, CA). Bands were detected with
ECL and ﬁlms according to the manufacturer
instructions (Du Pont-New England Nuclear,
Boston, MA). Films were scanned on a
ScanJet 6200C with Precision Scan Pro 1.02
(Hewlett Packard, Palo Alto, CA). 
Microarray data analysis. Affymetrix CEL
data ﬁles were imported into R, an open-source
statistical scripting language (http://www.
R-project.org; Ihaka and Gentleman 1996)
used in conjunction with the Bioconductor
project (http://www.bioconductor.org;
Gentleman et al. 2004). Normalized values
with robust multichip analysis background cor-
rection, quantile normalization and median
polish were calculated with AffylmGUI
(Wettenhall et al. 2006). AffylmGUI allows a
graphical user interface for the analysis of
Affymetrix microarray GeneChips using the
limma package (Smyth 2005) in R. A contrast
of treated–control samples was used to gener-
ate p-values and M-value [log2 (treated/
control)]. Probe sets with a p-value (p < 0.01)
after an adjustment with a false discovery rate
(FDR) 5% were judged by the limma package
to be differentially expressed between the
treated and control samples. If more than one
probe set for the same gene was identified,
their M-values (treatment/control ratios) were
averaged. The data discussed in this publica-
tion have been deposited in the National
Center for Biotechnology Information’s Gene
Expression Omnibus (GEO; http:// www.ncbi.
nlm.nih.gov/geo/; Edgar et al. 2002) and are
accessible through GEO series accession
number GSE4567. 
Biological pathway and network identiﬁ-
cation. Biological processes represented by
the differentially expressed genes were com-
piled using the Database for Annotation,
Visualization and Integrated Discovery
[DAVID 2.1 (http://apps1.niaid.nih.gov/
david/); Dennis et al. 2003]. Biological
pathways were compared to all available
Homo sapiens pathways speciﬁc to the Kyoto
Encyclopedia of Genes and Genomes (KEGG
2007). Only pathways with a p ≤ 0.05 calcu-
lated by DAVID were retained. 
Statistical analysis for nonmicroarray
data. All nonmicroarray data were presented as
mean ± SE. A paired t-test or a repeated
measures analysis of variance (ANOVA) was
used to compare differences between treatment
and control where appropriate. A p-value of
p < 0.05 was considered to be statistically sig-
niﬁcant. Statistical analysis was performed with
Statview 4.0 (SAS Institute Inc., Cary, NC).
Results
Identiﬁcation of differentially expressed genes
associated with UFP exposure. Using the sta-
tistical and ﬁltering algorithms described ear-
lier, we identiﬁed 664 differentially expressed
Affymetrix probe sets. We removed probe sets
that lacked an ENTREZ number or were
classified as undefined or hypothetical pro-
teins that reduced our list to 426 unique
genes, of which 320 were up-regulated and
106 were down-regulated. Using the pathway
analysis software, we found three KEGG bio-
logical pathways (p ≤ 0.05) overrepresented
from the differentially expressed gene list
(Tables 1–3). These pathways were the
cytokine–cytokine receptor interaction, Wnt
signaling, and MAPK signaling. Of note, the
cytokine–cytokine interaction pathway con-
tained the most number of genes, many of
which have been implicated in the pathogene-
sis of vascular disease for example, monocyte
chemotactit protein 1 (MCP-1, Unigene
accession no. 303649; http://www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db=unigene), IL-8,
chemokine ligand 1 (CXCL1, Unigene acces-
sion no. 789), chemokine ligand 2 (CXCL2,
Unigene accession no. 590921), chemokine
ligand 3 (CXCL3, Unigene accession no.
89690), and chemokine receptor 4 (CXCR4,
Unigene accession no. 421986). 
We also noted altered expression of sev-
eral genes related to coagulation. These alter-
ations included up-regulation of tissue factor
(F3) (2.7-fold) and coagulation factor II
receptor-like 2 (F2RL2) (1.5-fold) and down-
regulation of coagulation factor VIII-associ-
ated (intronic transcript) 1 (F8A1) (0.8-fold).
There were also additional genes associated
with the tissue factor (TF)–clotting indepen-
dent signaling pathway (Table 4). 
Q-PCR and verification of microarray
results. The expression of F3 was verified by
Q-PCR. Microarray results showed a 2.7-fold
up-regulation in F3, whereas Q-PCR showed a
3.3-fold up-regulation. HPAEC were exposed
to 0, 1, 10, and 100 µg/mL UFPs in vitro for
4 hr and showed signiﬁcant upregulation in a
dose-dependent manner (Figure 1). 
HPAEC were also exposed to water-
soluble and -insoluble fractions of UFPs for 2
and 24 hr. Both water-soluble and -insoluble
UFP fractions up-regulated the expression of
F3 dose dependently, especially at 24 hr post-
exposures (Figure 2A). The water-soluble
fraction tended to increase the expression of
F2RL2 (Figure 2B). For heme oxygenase
(HMOX1), which was upregulated in the
Up-regulation of tissue factor due to UFP exposure
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Table 3. MAPK signaling KEGG pathway (p = 0.05) identiﬁed with DAVID 2.1 from the list of differentially
expressed unique genes (p < 0.01) (FDR = 0.05). 
Accession no. Gene symbol Gene name Fold change
417962 DUSP4 dual speciﬁcity phosphatase 4 1.7
510225 RPS6KA5 ribosomal protein S6 kinase, polypeptide 5 1.6
25647 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog  1.6 
557403 IL1R1 interleukin-1 receptor, type I 1.6
432453 MAP3K8 mitogen-activated protein kinase kinase kinase 8 1.5
497200 PLA2G4A phospholipase A2, group IVA 1.5
278733 SOS1 son of sevenless homolog 1 1.3
438918 ACVR1B activin A receptor, type IB 1.3
525704 JUN v-jun sarcoma virus 17 oncogene homolog 1.3
149413 PPP3CC protein phosphatase 5 catalytic subunit, gama isoform 1.2
390428 MAP3K4 mitogen-activated protein kinase kinase kinase 4 0.9
1976 PDGFB viral (v-sis) oncogene homolog 0.8
186486 MAP3K5 mitogen-activated protein kinase kinase kinase 5 0.8
Gene annotations are from Unigene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene).
Table 4. Tissue factor clotting–independent mechanism associated genes from the list of differentially
expressed unique genes (p < 0.01) (FDR = 0.05). 
Accession no. Gene symbol Gene name Fold change
517617 MAFF v-maf musculoaponeurotic ﬁbrosarcoma oncogene homolog F 1.7
25292 JUNB jun B proto-oncogene 1.7
590958 FOSB FBJ murine osteosarcoma viral oncogene homolog B 1.5
132225 PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 1.5
155396 NRF2 nuclear factor (erythroid-derived 2)-like 2 1.3
534313 EGR3 early growth response 3 1.3
81328 NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells  1.3
inhibitor, alpha
252229 MAFG v-maf musculoaponeurotic ﬁbrosarcoma oncogene homolog G (avian) 1.2
326035 EGR1 early growth response 1 1.2
Gene annotations are from Unigene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene).microarray (2.5-fold), the water-soluble frac-
tion up-regulated HMOX1 at 24 hr after UFP
exposure (Figure 2D).
F8A1, which was down-regulated in the
microarray study, showed a signiﬁcant down-
regulation in the Q-PCR results by both solu-
ble and insoluble fractions at 2 hr postexposure
(Figure 2C). 
Up-regulation of TF protein expression by
UFP. To determine if the protein expression
of TF was up-regulated, HPAEC were incu-
bated with UFP for 18 hr and TF in the cell
lysate was measured by Western blot analysis.
As shown in Figure 3, UFPs increased TF
expression by more than 2-fold (Figure 3). 
Role of TF in UFP-induced cytokine
release. UFP exposure increased the release of
IL-8 by HPAEC by 1.7-fold. Pretreatment
with a blocking antibody against TF inhibited
the UFP-induced IL-8 release by more than
70% at 0.1 µg/mL of anti-TF (Figure 4A).
UFP also increased the release of IL-6 by
1.9-fold. Pretreatment with the blocking anti-
body against TF attenuated the IL-6 release
by approximately 30% at 0.1 µg/mL of
anti-TF (p = 0.01) (Figure 4B).
Discussion
Numerous epidemiologic studies have identi-
ﬁed a link between PM exposure with adverse
cardiovascular outcomes and increased mor-
tality (Borja-Aburto et al. 1998; Dockery
et al. 1993). Recent studies have shown a link
between PM exposure and oxidative stress,
which may impair endothelial-dependent
vasodilation as well as increased levels of ﬁb-
rinogen (an established risk factor for myocar-
dial infarction and stroke), C reactive protein,
IL-6, and IL-8 (Brook et al. 2003, 2004).
Despite ample evidence of a link between PM
exposure and cardiovascular morbidity and
mortality, our understanding of the biological
mechanisms for these adverse outcomes
remains incomplete. Our hypothesis in this
study was that the ultrafine fraction of PM,
which more likely would have direct contact
with pulmonary vasculature when inhaled
than ﬁne and course PM, is capable of induc-
ing transcriptional changes indicative of
endothelial cell dysfunction. Using microar-
ray analysis, we found 426 unique genes dif-
ferentially expressed after UFP exposure for
4 hr in HPAEC. Among these were genes
related to the coagulation–inﬂammation cir-
cuitry, including up-regulation of F3, F2RL2,
IL-6, and IL-8 and downregulation of F8A1.
There was also a group of genes that were
involved in the pathogenesis of vascular dis-
ease, including those associated with the clot-
ting independent signaling of F3, which
included v-fos FBJ murine osteosarcoma viral
oncogene homolog (FOS, Unigene accession
no. 25647; http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=unigene), v-jun sarcoma
virus 17 oncogene homolog (JUN, Unigene
accession # 525704), nuclear factor kappa-B-
cell, subunit 1 (NFKBIA, Unigene accession
no. 81328), and HMOX1. Additionally there
also were genes related to the CXC family of
chemokines (MCP-1, IL-8, CXCL1, CXCL2,
CXCL3, and CXCR4).
In higher organisms, the coagulation cas-
cade is activated to stop the loss of blood after
vascular injury by forming a fibrin clot.
Inappropriate activation of the coagulation
pathways, however, can promote intravascular
thrombosis (Chu 2006; Mackman 2005).
The blood coagulation cascade is composed
of intrinsic and extrinsic pathways. The
extrinsic pathway is an inducible signaling
cascade that is triggered by up-regulation of
TF upon inﬂammation or endothelial injury
(Chu 2006). This initiation process exposes
TF to factor VII and forms the tightly bound
TF-factor VII–activated complex, which then
activates factor X and generates small
amounts of thrombin (Busch et al. 2005).
The production of thrombin by the extrinsic
pathway is critical because it not only gener-
ates ﬁbrin from ﬁbrinogen (Davie et al. 1991;
Gailani and Broze 1991) but also amplifies
the intrinsic pathway. Our study showed that
UFPs or their water-soluble fractions induced
the gene and protein expression of TF.
Together with differential expression of other
coagulation-related genes, our in vitro study
raised the possibility that ambient UFP expo-
sure may activate the coagulation cascade.
Preliminary results from our UFP-controlled
human exposure study showed a 10–25%
increase in indicators of coagulation: pro-
thrombin fragment F1+2 and D-dimers
(unpublished observation). 
F3 expression is markedly increased within
arterial atherosclerotic plaques. Spontaneous
plaque rupture may trigger intravascular clot-
ting (Day et al. 2005) and may be a primary
cause of thrombus formation in the onset of
acute coronary syndromes (Ishibashi et al.
2003). Studies with an F3-deficient mouse
model suggest that thrombosis after arterial
injury is driven primarily by vascular wall F3
expression (Day et al. 2005; Ishibashi et al.
2003). Inactivation of the F3 factor VIIa com-
plex by F3 pathway–inhibitor or active
site–blocked factor VIIa has been shown to
reduce thrombus weight and increase patency
in a rabbit vein injury model (Himber et al.
2002). In our study, UFPs altered the expres-
sion of several coagulation-related genes in
Karoly et al.
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Figure 1. Q-PCR gene expression of tissue factor
(F3) in cell cultures exposed to UFPs (1, 10, and
100 µg/mL) for 4 hr. n = 4 additional experiments for
each timepoint and particle exposure. The line indi-
cates a mean ratio of 1.0 or no fold change between
treated (trt) and control (con) samples. Error bars
indicate mean ± SE. Statistical significance was
determined with the paired t-test. 
*Signiﬁcantly different from control samples, at p < 0.05.
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Figure 2. Effect of water-soluble and -insoluble fractions of UFP on gene expression of (A) tissue factor
(F3), (B) coagulation factor II receptor-like 2 (F2RL2), (C) coagulation factor VIII associated 1 (F8A1), and
(D) heme oxygenase (HMOX1). Abbreviations: con, control samples; trt, treated samples. Cell cultures
were exposed to water-soluble or -insoluble fractions of UFPs (µg/mL) for 2 or 24 hr. mRNA expression
was quantified by Q-PCR. n = 3 additional experiments for each time point and particle exposure. Error
bars indicate mean ± SE. 
*Signiﬁcant dose response by repeated measures, ANOVA at p < 0.05.favor of thrombus formation, that is, up-
regulation of F3, F2RL2, and down-regulation
of thrombomodulin (THBD, Unigene acces-
sion no. 2030; http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=unigene). These changes
provide biologically plausible mechanisms by
which UFPs may promote thrombus forma-
tion, namely, activating the TF-mediated
extrinsic coagulation pathway and inhibiting
the anticoagulant effects of protein C through
suppression of thrombomodulin (Nemerson
1988; Van der Meeren et al. 2003). 
TF may also produce biological effects via
clotting-independent mechanisms (Rickles
et al. 2003; Versteeg et al. 2003). After cell
activation, the F3 gene is induced early as a
result of the binding of transcription factors,
for example, specificity protein-1 (SP-1),
activator protein-1 (AP-1), and nuclear
factor-kB, to the promoter region of the F3
gene. The functions of clotting-independent
TF pathways are not entirely clear, but regu-
lation of angiogenesis appears to be a major
one. TF is known to induce vascular endothe-
lial growth factor (VEGF), one of the most
potent regulators of angiogenesis, which in
turn up-regulates the expression of TF by
activating the early growth response-1 gene
(Mechtcheriakova et al. 1999). In tumor-
related endothelial cells, decreased PI3-K
activity concurrent with increased p38 and
ERK1/2 MAPK activity enhances F3 expres-
sion by VEGF (Blum et al. 2001). In our
study, UFPs altered the expression of many
of the genes in these processes, including
FOS (1.6-fold), JUN (1.3-fold), NFKBIA
(1.3-fold), and early growth response-1
(EGR-1, Unigene accession no. 326035;
http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=unigene) (1.2-fold), indicating poten-
tial involvement in activation of clotting-
independent mechanisms of TF by UFPs. 
Other findings in our study further sup-
port the role of PM in the pathogenesis of
vascular diseases. For example, we found that
UFPs up-regulated genes in the CXC family
of chemokines that have been implicated in
the pathogenesis of vascular disease. These
genes include MCP-1, IL-8, CXCL1, CXCL2,
CXCL3, and CXCR4. MCP-1, which was up-
regulated 2.6-fold, has been implicated in the
development of vascular disease ranging from
arterial injury to the formation of athero-
sclerosis (Charo and Taubman 2004).
Overexpression of MCP-1 in vessel-wall
macrophages led to increased foam cells for-
mation and increased atherosclerosis (Aiello
et al. 1999). Deletion of MCP-1 in low-
density lipoprotein receptor-null mice and
mice expressing human apolipoprotein B
attenuated the progression of dietary-induced
atherosclerosis (Gosling et al. 1999; Gu et al.
1998). Acute coronary syndrome patients
with the highest levels of MCP-1 had a signif-
icantly increased risk of death or myocardial
infarction over 2 months of follow-up
(de Lemos et al. 2003). IL-8 also has been
linked to the development of early atheroscle-
rotic lesions in the vessels. IL-8, a monocyte
agonist, is present in macrophage-rich athero-
sclerotic plaques (Gerszten et al. 1998, 1999).
The expression of these chemokines may
enhance the adhesion of circulating mono-
cytes on vascular endothelial cells and partici-
pate in atherogenesis (Hagiwara et al. 1998). 
It is also well established that there is
cross-talk between the coagulation pathways
and inﬂammation in sepsis (Hack 2000; Levi
and van der Poll 2005). Infusion of site-inac-
tivated factor VIIa reduced production of
cytokines, including IL-6, IL-8 and soluble
TNF (tumor necrosis factor) receptor 1 in a
baboon model of sepsis (Miller et al. 2002;
Welty-Wolf et al. 2001). Genetically modi-
ﬁed mice expressing low levels of F3 exhibited
reduced IL-6 expression and increased sur-
vival during endotoxemia (Pawlinski and
Mackman 2004). We now show that there
may also be a link between the F3 pathways
and inflammation after UFP exposure. This
was supported by the ﬁndings that the UFP-
induced production of IL-6 and IL-8 was
attenuated by a blocking antibody against TF.
Conversely, TF expression can be induced by
inflammatory mediators such as IL-6, IL-8,
and MCP-1 (Busch et al. 2005), all of which
were up-regulated in our microarray results by
2.30, 2.50, and 2.6-fold, respectively.
It remains controversial whether PM can
have direct contact with pulmonary vascular
endothelial cells when inhaled. Recent studies
have shown that ultraﬁne carbon black particles
may be able to pass from the lung into the sys-
temic circulation (Nemmar et al. 2001, 2002a;
Oberdörster et al. 2002), although the mecha-
nisms for the transport of these insoluble parti-
cles are unclear. For the UFPs derived from the
natural environment, such as those used in our
study, the components in the water-soluble
fraction may more easily permeate the alveolar
capillary barrier via paracellular pathways or
metal transporters. Indeed, the water-soluble
fractions of UFPs were sufﬁcient to induce the
expression of F3. The active components in the
water-soluble fractions of UFPs, however, are
unknown and would require future studies. 
In this study, we showed that UFPs at con-
centrations of 10 µg/mL were sufficient to
induce the gene expression of F3. These con-
centrations are higher than the usual ambient
level. In Chapel Hill, the ambient UFP concen-
tration is approximately 5,000 particles/cm3
(1.6 µg/m3) (unpublished observations). The
concentration of UFPs, however, may increase
50- to 100-fold during indoor smoking and
cooking (Afshari et al. 2005; Dennekamp et al.
2001). If a person works in the latter environ-
ment for 4 hr with an average ventilation of
10 L/min, the concentration of UFPs to which
alveolar epithelial cells may be exposed in vivo
may be as high as 10–20 µg/mL, assuming the
volume of epithelial lining ﬂuid is 20–40 mL
(Rennard et al. 1986). Once UFPs deposit on
the lung epithelial cells, the water-soluble frac-
tions of UFPs may reach the endothelial cells
and stimulate them to express F3. 
In summary, using gene profiling, we
found that UFPs induced genes that have
been implicated in the pathogenesis of vascu-
lar disease, including those linked to clotting-
dependent and -independent signaling
pathways mediated by TF as well as by the
CXC family of chemokines. These results sup-
port our hypotheses that UFP exposure may
induce endothelial cell dysfunction, leading to
vascular changes, and suggest that exposure to
high concentrations of UFP may be consid-
ered a risk factor for the development of
cardiovascular disease.
Up-regulation of tissue factor due to UFP exposure
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Figure 3. UFP-induced tissue factor protein expres-
sion in HPAEC. HPAEC cultures were incubated
with 0 or 100 µg/mL UFPs for 16 hr. Fifty micro-
grams of protein were loaded and measured for
tissue factor expression by Western blotting.
Results are from three independent experiments.
47 kDa
100 μg/mL UFP
Tissue factor protein
–––+++
Figure 4. Production of IL-8 (A) and IL-6 (B) protein expression from HPAEC after exposure to TF-blocking
antibody and UFPs. Abbreviations: con, control group; diff, difference; trt, treated group. Cell cultures were
preincubated with 0, 0.05, and 0.1 µg/mL TF-blocking antibody followed by 16 hr UFP exposure (100 µg/mL).
Values are expressed as the mean difference (diff) between treated (trt) and control (con) samples as
measured by ELISA. n = 3 independent experiments for each sample. Error bars indicate mean ± SE. 
*Signiﬁcant at p < 0.05 vs. no antibody by the paired t-test.
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